Appointment of Financial Adviser for Strategic Review
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Chimeric Therapeutics Limited has appointed Hawkesbury Partners as its Independent Financial Adviser to conduct a strategic review aimed at maximizing shareholder value. The Board is exploring various strategic and funding options, including partnerships and asset sales, to enhance the company's market position. Hawkesbury Partners will evaluate opportunities to realize value from Chimeric's clinical programs and infrastructure investments. The company emphasizes that there is no guarantee of any transactions resulting from this review process.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Chimeric Therapeutics Limited on 6ix
Earlier from Chimeric Therapeutics
- CHM announces positive Phase 1/2 data at ASCO
- Minaris Delivers 100% Manufacturing and Release Success for Chimeric Therapeutics' CDH17 Autologous CAR‑T Program
- Consolidation/Split - CHM
- Chimeric receives $1.8 M advance on FY26 R&D tax incentive
- Half Year Report and Appendix 4D 31 December 2025
Later from Chimeric Therapeutics
- CHM CDH17 Phase 1 clinical trial update - New DL 3 data
- Investor Presentation
- Chimeric receives $1.62M advance on FY26 R&D tax incentive
- Quarterly Activities/Appendix 4C Cash Flow Report
- Application for quotation of securities - CHM
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics